BioDelivery +27% AH on positive clinical trial results for pain relief drug

|About: BioDelivery Sciences Intern... (BDSI)|By:, SA News Editor

BioDelivery Sciences (BDSI) +27.2% AH after the company and Endo Health Solutions (ENDP) announce a late-stage clinical trial for their new chronic pain medication showed significantly improved pain relief.

The Phase III trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to a placebo.

ENDP +2.4% AH.